British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017

Professor Carmine Pariante

Declaration of Interests

  1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
  2. No
  3. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
  4. No
  5. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
  6. No
  7. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
  8. Consultant to Eleusis Benefit Corporation
  9. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
  10. No
  11. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
  12. - Research funding from Johnson & Johnson for research on depression and inflammation
    - Research funding from Wellcome/MRC Consortia that include GSK, Johnson & Johnson, Lundbeck and Pfizer
  13. Have you, in the past three years, had membership of the speakers' bureau for any company?
  14. One talk, by Lundbeck
  15. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
  16. No
  17. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
  18. No
  19. Have you, in the past three years, recruited patients for industry-sponsored studies?
  20. No
  21. If there is anything else you feel it necessary to disclose, please provide details below:
  22. Around 10% of the funding supporting Professor Pariante’s research comes from pharmaceutical companies interested in the development of new antidepressants; the remaining 90% comes from the UK Medical Research Council, the NHS, the European Commission and research charities

Form completed on 24th January 2017